Trials mtn

Respond to Pre-Award Requests. After Award. Contract Solicitations. Contact the Office of Acquisitions. Most Recent Edition. Browse by Edition Date. Search All Funding News. Clinical Trials. Find a Clinical Trial. Participant's Guide to Clinical Trials. Participant Testimonials. Laboratory of Infectious Diseases.

Primary Immune Deficiency Clinic. Vaccine Research Center Clinical Studies. Vaccine Clinical Studies Safeguards. News Releases. Media Contacts. Media Resources. Fauci in the News. Congressional Testimony. Past Events. Kinyoun Lecture Series. LaMontagne Lecture Series. Hill Lecture Series. Director, Anthony Fauci, M. Profiles, Awards and Honors. Laboratory of Immunoregulation. Previous Directors. Office of the Director. Division of AIDS. Division of Allergy, Immunology, and Transplantation.

Division of Microbiology and Infectious Diseases. Division of Extramural Activities. Division of Clinical Research. Division of Intramural Research. Vaccine Research Center. Organizational Chart. Joseph J. Katina Mulroy, formerly of the town of Emmet, faces charges of attempted first-degree intentional homicide, intentionally pointing a firearm at a law enforcement officer, resisting or obstructing an officer and disorderly conduct in connection with the Jan. The suspect, later identified as Mulroy, was a guest at the hotel but had overstayed.

Police say she pulled out a gun when asked by hotel management to leave the property. A hotel representative immediately called and negotiators worked to persuade Mulroy to surrender for more than six hours.

When negotiations failed, officers encountered Mulroy in a hallway holding a semi-automatic handgun. According to court documents, Mulroy allegedly did not comply with orders to drop the weapon and instead faced police with the firearm in both hands. Funding is provided through a Cooperative Agreement UM1 mechanism. Because the effectiveness of a product is also dependent on its use, behavioral and social science is embedded within each microbicide study to gain understanding of the needs and desires of different high-risk groups.

MTN's research agenda includes populations considered among those at highest risk, including women in sub-Saharan Africa, adolescents, pregnant and breastfeeding women, transgender women, and men who have sex with men.

Collectively, more than 12, research participants have taken part in MTN studies. As sister studies, the two trials are designed to provide the evidence to support licensure of the dapivirine vaginal ring for preventing HIV in women.

Each MTN study has its own protocol team consisting of investigators from clinical trial sites and representatives from different specialty areas and disciplines.

MTN relies on three working groups to ensure scientific quality and consideration of community perspectives, including:. MTN-affiliated researchers and partners work within a unique infrastructure specifically designed to facilitate the research required to support licensure of the tested products for widespread use.

MTN brings together international investigators and community and industry partners whose work is focused on the rigorous evaluation of promising microbicides — products applied inside the vagina or rectum to help prevent the sexual transmission of HIV. These include multi-purpose products for preventing both HIV and unintended pregnancy and others to protect against HIV and different sexually transmitted infections. MTN studies are designed specifically to support the potential licensure and regulatory approval of these products for populations particularly vulnerable to HIV.